Your browser is no longer supported. Please, upgrade your browser.
Settings
FDMT [NASD]
4D Molecular Therapeutics, Inc.
Index- P/E- EPS (ttm)- Insider Own2.80% Shs Outstand27.02M Perf Week-7.11%
Market Cap684.80M Forward P/E- EPS next Y-3.68 Insider Trans-9.94% Shs Float18.27M Perf Month-30.57%
Income- PEG- EPS next Q-1.11 Inst Own63.30% Short Float6.48% Perf Quarter-29.42%
Sales13.61M P/S50.31 EPS this Y77.30% Inst Trans14.47% Short Ratio4.59 Perf Half Y-21.31%
Book/sh8.29 P/B2.58 EPS next Y-37.40% ROA- Target Price50.33 Perf Year-
Cash/sh5.06 P/C4.23 EPS next 5Y31.50% ROE- 52W Range21.25 - 55.11 Perf YTD-48.32%
Dividend- P/FCF- EPS past 5Y- ROI-22.10% 52W High-61.13% Beta-
Dividend %- Quick Ratio14.60 Sales past 5Y- Gross Margin- 52W Low0.80% ATR1.62
Employees121 Current Ratio14.60 Sales Q/Q-90.40% Oper. Margin- RSI (14)32.50 Volatility7.28% 6.07%
OptionableYes Debt/Eq0.00 EPS Q/Q88.00% Profit Margin- Rel Volume0.90 Prev Close22.05
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume257.75K Price21.42
Recom2.00 SMA20-10.38% SMA50-21.99% SMA200-31.35% Volume233,047 Change-2.86%
Jan-05-21Initiated Goldman Neutral $44
Jan-05-21Initiated Evercore ISI Outperform $70
Jan-05-21Initiated BofA Securities Buy $47
Nov-29-21 04:00PM  
Nov-25-21 05:52AM  
Nov-23-21 04:05PM  
Nov-15-21 06:01AM  
Nov-10-21 04:01PM  
Oct-28-21 09:06PM  
Oct-26-21 05:52PM  
08:30AM  
08:27AM  
Oct-25-21 04:03PM  
Oct-10-21 03:50PM  
Oct-07-21 11:22AM  
Oct-06-21 08:27AM  
07:30AM  
07:30AM  
Sep-29-21 04:01PM  
Sep-24-21 07:03AM  
Aug-27-21 09:56AM  
Aug-12-21 04:04PM  
Jul-26-21 07:50PM  
Jun-28-21 09:38AM  
Jun-24-21 07:01AM  
Jun-07-21 07:00AM  
Jun-03-21 07:00AM  
May-13-21 04:03PM  
May-12-21 05:30PM  
May-10-21 04:35AM  
May-04-21 04:02PM  
Apr-30-21 07:05AM  
Apr-27-21 04:31PM  
Apr-26-21 10:16AM  
Apr-20-21 08:45AM  
Mar-25-21 04:02PM  
Mar-11-21 01:27AM  
Mar-09-21 08:03AM  
Dec-16-20 04:52PM  
Dec-15-20 04:05PM  
Dec-11-20 05:39PM  
05:25PM  
4D Molecular Therapeutics, Inc., a clinical-stage gene therapy company, develops product candidates using its adeno-associated viruses vectors. It develops a portfolio of gene therapy product candidates focuses in three therapeutic areas: ophthalmology, cardiology, and pulmonology. The company has three product candidates that are in clinical trials: 4D-125 that is in a Phase 1/2 clinical trial for the treatment of X-linked retinitis pigmentosa; 4D-110 that is in a Phase 1 clinical trial for the treatment of choroideremia; and 4D-310, which is in a Phase 1/2 clinical trial for the treatment of Fabry disease. Its two IND candidates are 4D-150 for the treatment of wet age-related macular degeneration and 4D-710 for the treatment of cystic fibrosis lung disease. 4D Molecular Therapeutics, Inc. has research and collaboration arrangements with uniQure; Benitec; CRF; Roche; CFF; and AstraZeneca. The company was founded in 2013 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
SCHAFFER DAVIDDirectorOct 22Sale31.001,90058,893901,215Oct 22 09:42 PM
SCHAFFER DAVIDDirectorOct 21Sale31.5622,820720,156903,115Oct 22 09:42 PM
SCHAFFER DAVIDDirectorOct 20Sale31.0211,565358,771925,935Oct 22 09:42 PM
SCHAFFER DAVIDDirectorSep 30Sale26.9112,385333,250937,500Oct 01 04:34 PM
SCHAFFER DAVIDDirectorSep 29Sale28.6116,871482,614949,885Oct 01 04:34 PM
SCHAFFER DAVIDDirectorSep 28Sale30.5313,912424,693966,756Sep 29 04:05 PM
SCHAFFER DAVIDDirectorSep 27Sale32.8919,332635,826980,668Sep 29 04:05 PM
Moretti August JChief Financial OfficerApr 12Option Exercise9.411,0009,4102,000Apr 14 04:32 PM